Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Sarcoma patients share their experience on a second chemo round

NCT ID NCT06050434

Knowledge-focused Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early This study
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study aimed to track how soft tissue sarcoma patients feel—symptoms, side effects, and quality of life—when they receive trabectedin chemotherapy again after a break. Only 7 patients were enrolled before the study was stopped early. The goal was to gather real-world patient feedback to guide future treatment decisions.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
trabectedin (chemotherapy)
What this could lead to
If successful, this study could help doctors understand how sarcoma patients feel during a second round of trabectedin, potentially improving care decisions.
What could go wrong
This was a small, terminated study with only 7 participants, so results may be limited and not apply to all patients. It focuses on patient reports, not on proving the drug works.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

7 people

The number who actually took part.

Started

Oct 2023

Finished

Jul 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult GISAR participants with Trabectedin-pretreated soft tissue sarcomas and rechallenge with at least one cycle of Trabectedin in any line of therapy, with the interval between Trabectedin interruption and Trabectedin rechallenge being at least 3 months.

Ages

18 years and older

Sex

Anyone

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Enrolled participant of the GISAR registry and their sub-studies * Patient with histologically confirmed soft tissue sarcomas * Pretreatment with Trabectedin, termination of this therapy regardless of reason * Planned rechallenge or started rechallenge with Trabectedin in any line of therapy within 2 weeks before inclusion * Interval between last Trabectedin treatment and Trabectedin rechallenge at least 3 months Exclusion Criteria: * Not able to understand all implications of study participation * No written informed consent * Age ≤ 18 years

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Soft tissue sarcoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

sarcoma soft tissue sarcoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Soft tissue sarcoma

Contacts and locations

Locations

  • Frankfurt Universitätsklinikum

    Frankfurt am Main, Germany

  • HELIOS KLinikum Bad Saarow

    Bad Saarow, Germany

  • HELIOS Klinikum Berlin Buch

    Berlin, Germany

  • Uniklinikum Leipzig

    Leipzig, Germany

  • Universitätsklinikum Tübingen

    Tübingen, Germany

  • Universitätsmedizin Greifswald

    Greifswald, Germany

  • Universitätsmedizin Göttingen

    Göttingen, Germany

  • Universitätsmedizin Mainz

    Mainz, Germany

  • Westfälische Wilhelms-Universität Münster

    Münster, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.